Pieris Pharmaceuticals Inc - רווח למניה לשנה מתגלגלת PIRS

Pieris Pharmaceuticals (PIRS) develops proteins to combat tumors and lung pathologies, yet a lack of recurring revenue leaves the company dependent on test results. The development of new drugs is accelerating through strategic alliances and the Anticalin platform. Management is currently cutting ancillary projects to preserve assets. The trailing twelve months (ttm) earnings per share growth rate exhibits sideways movement, with the latest reading at 56.10.
pieris.com - פילוחים אנליטיים ומדדי מפתח (PIRS)

Pieris Pharmaceuticals (PIRS) develops high-precision anticalin platforms to combat cancer and lung pathologies. This chart of annual EPS TTM growth illustrates the net profit per share dynamics over a twelve-month period. The metric calculates the percentage change in earnings, allowing investors to filter out market noise from the sustainable trend. The steady growth of the line confirms the effective capitalization of scientific research. For the investor, this indicator serves as a marker of the real return on investment in biomedical innovations.